Microbot Medical® Secures U.S. Based Logistics Partner to Support the Commercialization of Its LIBERTY® Endovascular Robotic System

Core Insights - Microbot Medical Inc. is set to launch its LIBERTY Endovascular Robotic System in Q4 2025, with a broader release planned for April 2026 during a major conference [1][4] Group 1: Company Overview - Microbot Medical Inc. specializes in innovative medical devices, focusing on transforming endovascular procedures through advanced robotic technology [4] - The LIBERTY System is the first single-use, remotely operated robotic solution designed for precision, efficiency, and safety [4] Group 2: Partnership and Logistics - The company has partnered with a U.S.-based third-party logistics (3PL) provider to support the commercialization of the LIBERTY System, ensuring effective inventory management and customer support [1][2] - The 3PL provider specializes in the medical device industry, allowing the company to leverage its proximity to key markets and maintain inventory in a climate-controlled warehouse [2] Group 3: Operational Strategy - The partnership with an established logistics provider is expected to enhance the company's go-to-market initiatives, making the commercial launch of LIBERTY more efficient [3]